1.
Could SARS-CoV-2 Infection Be a Novel Risk Factor for Multiple Sclerosis? Magdy R, Hussein M.
Neuroimmunomodulation. 2022 Mar 2:1-4. doi: 10.1159/000521891. Online ahead of print.
PMID: 35235939 Review.
2.
Aquatic exercise for persons with MS: Patient-reported preferences, obstacles and recommendations. Chen MH, DeLuca J, Sandroff BM, Genova HM.
Mult Scler Relat Disord. 2022 Feb 20;60:103701. doi: 10.1016/j.msard.2022.103701. Online ahead of print.
PMID: 35235900
3.
Reduced cognitive function contributes to economic burden of multiple sclerosis. Maltby VE, Lea RA, Reeves P, Saugbjerg B, Lechner-Scott J.
Mult Scler Relat Disord. 2022 Feb 22;60:103707. doi: 10.1016/j.msard.2022.103707. Online ahead of print.
PMID: 35235899
4.
Neurological symptoms and disorders following electrical injury: A register-based matched cohort study. Nielsen KJ, Carstensen O, Kærgaard A, Vestergaard JM, Biering K.
PLoS One. 2022 Mar 2;17(3):e0264857. doi: 10.1371/journal.pone.0264857. eCollection 2022.
PMID: 35235596
5.
Failed remyelination of the nonhuman primate optic nerve leads to axon degeneration, retinal damages, and visual dysfunction. Sarrazin N, Chavret-Reculon E, Bachelin C, Felfli M, Arab R, Gilardeau S, Brazhnikova E, Dubus E, Yaha-Cherif L, Lorenceau J, Picaud S, Rosolen S, Moissonnier P, Pouget P, Baron-Van Evercooren A.
Proc Natl Acad Sci U S A. 2022 Mar 8;119(10):e2115973119. doi: 10.1073/pnas.2115973119. Epub 2022 Mar 2.
PMID: 35235463
6.
Antibody cross-reactivity between casein and myelin-associated glycoprotein results in central nervous system demyelination. Chunder R, Weier A, Mäurer H, Luber N, Enders M, Luber G, Heider T, Spitzer A, Tacke S, Becker-Gotot J, Kurts C, Iyer R, Ho PP, Robinson WH, Lanz TV, Kuerten S.
Proc Natl Acad Sci U S A. 2022 Mar 8;119(10):e2117034119. doi: 10.1073/pnas.2117034119. Epub 2022 Mar 2.
PMID: 35235454
7.
Nephronectin influences EAE development by regulating Th17/Treg balance via reactive oxygen species. Honda M, Segawa T, Ishikawa K, Maeda M, Saito Y, Kon S.
Am J Physiol Cell Physiol. 2022 Mar 2. doi: 10.1152/ajpcell.00376.2021. Online ahead of print.
PMID: 35235429
8.
Osteopontin in autoimmune disorders: current knowledge and future perspective. Xu C, Wu Y, Liu N.
Inflammopharmacology. 2022 Mar 2. doi: 10.1007/s10787-022-00932-0. Online ahead of print.
PMID: 35235108 Review.
9.
Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod. Achiron A, Mandel M, Gurevich M, Dreyer-Alster S, Magalashvili D, Sonis P, Dolev M, Menascu S, Harari G, Flechter S, Falb R.
J Neurol. 2022 Mar 2. doi: 10.1007/s00415-022-11030-0. Online ahead of print.
PMID: 35235002
10.
An automated method for precise axon reconstruction from recordings of high-density micro-electrode arrays. Buccino AP, Yuan X, Emmenegger V, Xue X, Gänswein T, Hierlemann A.
J Neural Eng. 2022 Mar 2. doi: 10.1088/1741-2552/ac59a2. Online ahead of print.
PMID: 35234667
11.
Dietary patterns and risk of multiple sclerosis: Results of a double-center case-control study in Iran. Rouzitalab T, Shivappa N, Daneshzad E, Izadi A, Sanoobar M, Khandouzi N, Shiri-Shahsavar MR, Khalili M.
Nutr Health. 2022 Mar 2:2601060221082379. doi: 10.1177/02601060221082379. Online ahead of print.
PMID: 35234101
12.
Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis. Yu H, Graham G, David OJ, Kahn JM, Savelieva M, Pigeolet E, Das Gupta A, Pingili R, Willi R, Ramanathan K, Kieseier BC, Häring DA, Bagger M, Soelberg Sørensen P.
CNS Drugs. 2022 Mar 1. doi: 10.1007/s40263-021-00895-w. Online ahead of print.
PMID: 35233753
13.
Adaptive immunity, chronic inflammation and the clock. Gray KJ, Gibbs JE.
Semin Immunopathol. 2022 Mar 1. doi: 10.1007/s00281-022-00919-7. Online ahead of print.
PMID: 35233691 Review.
14.
Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination. Quan L, Uyeda A, Muramatsu R.
Inflamm Regen. 2022 Mar 2;42(1):7. doi: 10.1186/s41232-022-00193-y.
PMID: 35232486 Review.
15.
The role of Bordetella pertussis in the development of multiple sclerosis. Majzoobi MM, Macvandi MR, Basir HG, Sanaei Z, Mazaheri S, Afza M, Arabestani MR.
BMC Neurol. 2022 Mar 1;22(1):70. doi: 10.1186/s12883-022-02606-4.
PMID: 35232387
16.
Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits. Graf J, Ng HS, Zhu F, Zhao Y, Wijnands JM, Evans C, Fisk JD, Marrie RA, Tremlett H.
Mult Scler. 2022 Mar 1:13524585221078497. doi: 10.1177/13524585221078497. Online ahead of print.
PMID: 35232298
17.
Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD. Dinoto A, Sechi E, Ferrari S, Gajofatto A, Orlandi R, Solla P, Maccabeo A, Maniscalco GT, Andreone V, Sartori A, Manganotti P, Rasia S, Capra R, Mancinelli CR, Mariotto S.
Mult Scler Relat Disord. 2022 Feb;58:103424. doi: 10.1016/j.msard.2021.103424. Epub 2021 Nov 22.
PMID: 35216793 Free PMC article.
18.
Recent Advances on Multivalent Carbon Nanoform-Based Glycoconjugates. Ramos-Soriano J, Ghirardello M, Galan MC.
Curr Med Chem. 2022;29(7):1232-1257. doi: 10.2174/0929867328666210714160954.
PMID: 34269658 Review.
19.
The influence of lifestyle factors on miRNA expression and signal pathways: a review. Panico A, Tumolo MR, Leo CG, Donno A, Grassi T, Bagordo F, Serio F, Idolo A, Masi R, Mincarone P, Sabina S.
Epigenomics. 2021 Jan;13(2):145-164. doi: 10.2217/epi-2020-0289. Epub 2020 Dec 23.
PMID: 33355508 Review.
1.
The burden of multiple sclerosis among postpartum women and self management’s challenges: Pilot study of supportive program. Kamel AD, Ghani RMA, Alanazi MR, Metwaly SM, Ahmed SM, Ibrahim SM.
Mult Scler Relat Disord. 2022 Feb 23;60:103694. doi: 10.1016/j.msard.2022.103694. Online ahead of print.
PMID: 35231803
2.
Impact of anti-PDGFRα antibody surface functionalization on LNC uptake by oligodendrocyte progenitor cells. Labrak Y, Heurtault B, Frisch B, Saulnier P, Lepeltier E, Miron VE, Muccioli GG, des Rieux A.
Int J Pharm. 2022 Feb 26:121623. doi: 10.1016/j.ijpharm.2022.121623. Online ahead of print.
PMID: 35231547
3.
Pulmonary Langerhans cell histiocystosis (PLCH) and lymphangioleiomyomatosis (LAM) have circulating cells with loss of heterozygosity of the TSC2 gene. Elia D, Torre O, Vasco C, Geginat J, Abrignani S, Bulgheroni E, Carelli E, Cassandro R, Pacheco-Rodriguez G, Steagall WK, Moss J, Harari S.
Chest. 2022 Feb 26:S0012-3692(22)00398-1. doi: 10.1016/j.chest.2022.02.032. Online ahead of print.
PMID: 35231481
4.
The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study. Bonacchi R, Meani A, Pagani E, Marchesi O, Filippi M, Rocca MA.
J Neurol. 2022 Mar 1. doi: 10.1007/s00415-022-11021-1. Online ahead of print.
PMID: 35230471
5.
Development of an age-adjusted model for blood neurofilament light chain. Harp C, Thanei GA, Jia X, Kuhle J, Leppert D, Schaedelin S, Benkert P, von Büdingen HC, Hendricks R, Herman A.
Ann Clin Transl Neurol. 2022 Mar 1. doi: 10.1002/acn3.51524. Online ahead of print.
PMID: 35229997
6.
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, Giacomini PS, Saccà F, Mancione L, Zielman R, Bagger M, Das Gupta A, Häring DA, Jehl V, Kieseier BC, Pingili R, Stoneman D, Su W, Willi R, Kappos L.
Mult Scler. 2022 Mar 1:13524585221079731. doi: 10.1177/13524585221079731. Online ahead of print.
PMID: 35229668
7.
Partners in crime: Proteins implicated in RNA repeat expansion diseases. Baud A, Derbis M, Tutak K, Sobczak K.
Wiley Interdiscip Rev RNA. 2022 Feb 28:e1709. doi: 10.1002/wrna.1709. Online ahead of print.
PMID: 35229468 Review.
8.
The role of NK and NKT cells in the pathogenesis and improvement of multiple sclerosis following disease-modifying therapies. Ahmadi A, Fallah Vastani Z, Abounoori M, Azizi M, Labani-Motlagh A, Mami S, Mami S.
Health Sci Rep. 2022 Jan 24;5(1):e489. doi: 10.1002/hsr2.489. eCollection 2022 Jan.
PMID: 35229046 Free PMC article. Review.
9.
Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey. Caseby SCL, Woodhouse FA, Montgomery SM, Kroes MA, Duddy ME.
Health Sci Rep. 2022 Jan 23;5(1):e474. doi: 10.1002/hsr2.474. eCollection 2022 Jan.
PMID: 35229042 Free PMC article.
10.
[A case of sporadic amyotrophic lateral sclerosis (ALS) with Senataxin (SETX) gene variant]. Beppu S, Ikenaka K, Yabumoto T, Todo K, Hashiguchi A, Takashima H, Mochizuki H.
Rinsho Shinkeigaku. 2022 Feb 25. doi: 10.5692/clinicalneurol.cn-001675. Online ahead of print.
PMID: 35228463 Japanese.
11.
Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry. Bossart J, Kamm CP, Kaufmann M, Stanikić M, Puhan MA, Kesselring J, Zecca C, Gobbi C, Rapold I, Kurmann R, Ammann S, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR).
Mult Scler Relat Disord. 2022 Feb 21;60:103706. doi: 10.1016/j.msard.2022.103706. Online ahead of print.
PMID: 35228114
12.
Phosphoproteome Profiling of the Receptor Tyrosine Kinase MuSK Identifies Tyrosine Phosphorylation of Rab GTPases. Budayeva HG, Sengupta-Ghosh A, Phu L, Moffat JG, Ayalon G, Kirkpatrick DS.
Mol Cell Proteomics. 2022 Feb 25:100221. doi: 10.1016/j.mcpro.2022.100221. Online ahead of print.
PMID: 35227894
13.
Resolving inflammatory links between myocardial infarction and vascular dementia. Thorp EB, Flanagan ME, Popko B, DeBerge M.
Semin Immunol. 2022 Feb 25:101600. doi: 10.1016/j.smim.2022.101600. Online ahead of print.
PMID: 35227567 Review.
14.
Incentivizing Prescription Drug Switching to Reduce Patient and Health Plan Spending: A Microsimulation Model. Yeung K, Ulloa E.
Value Health. 2022 Mar;25(3):427-434. doi: 10.1016/j.jval.2021.08.012. Epub 2021 Oct 1.
PMID: 35227455
15.
The neurovascular unit in leukodystrophies: towards solving the puzzle. Zarekiani P, Nogueira Pinto H, Hol EM, Bugiani M, de Vries HE.
Fluids Barriers CNS. 2022 Feb 28;19(1):18. doi: 10.1186/s12987-022-00316-0.
PMID: 35227276 Review.
1.
Fractal analysis in the quantification of medical imaging associated with multiple sclerosis pathology. Paun MA, Nichita MV, Paun VA, Paun VP.
Front Biosci (Landmark Ed). 2022 Feb 14;27(2):66. doi: 10.31083/j.fbl2702066.
PMID: 35227009
2.
MS-driven metabolic alterations are recapitulated in iPSC-derived astrocytes. Ghirotto B, Oliveira DF, Cipelli M, Basso PJ, de Lima J, Breda CNS, Ribeiro HC, Silva CCC, Sertié AL, Oliveira AER, Hiyane MI, Caldini EG, Sussulini A, Nakaya HI, Kowaltowski AJ, Oliveira EML, Zatz M, Câmara NOS.
Ann Neurol. 2022 Feb 28. doi: 10.1002/ana.26336. Online ahead of print.
PMID: 35226368
3.
Acute cerebellitis requiring posterior fossa decompression after COVID-19 vaccination in an ocrelizumab-treated patient with multiple sclerosis. Brecl Jakob G, Savšek L, Meglič B.
Neurol Sci. 2022 Feb 28. doi: 10.1007/s10072-022-05966-4. Online ahead of print.
PMID: 35226212 No abstract available.
4.
Interventions for Instrumental Activities of Daily Living Among Adults With Multiple Sclerosis: A Systematic Review. Cunningham R, Uyeshiro Simon A.
Am J Occup Ther. 2022 Mar 1;76(2):7602205130. doi: 10.5014/ajot.2022.049092.
PMID: 35226064
5.
Recent Considerations on Gaming Console Based Training for Multiple Sclerosis Rehabilitation. Celesti A, Cimino V, Naro A, Portaro S, Fazio M, Villari M, Calabró RS.
Med Sci (Basel). 2022 Feb 11;10(1):13. doi: 10.3390/medsci10010013.
PMID: 35225946
6.
Successful desensitization to alemtuzumab, with flow cytometric analysis of peripheral blood cells. Costa Carvalho J, Macário MC, Batista S, Alen Coutinho I, Laranjeira P, Loureiro C, Paiva A, Todo Bom A.
J Investig Allergol Clin Immunol. 2022 Feb 17:0. doi: 10.18176/jiaci.0795. Online ahead of print.
PMID: 35225791 No abstract available.
7.
Relationship between optical coherence tomography angiography and visual evoked potential in patients with multiple sclerosis. Ava S, Tamam Y, Hazar L, Karahan M, Erdem S, Dursun ME, Keklikçi U.
Indian J Ophthalmol. 2022 Mar;70(3):873-878. doi: 10.4103/ijo.IJO_431_21.
PMID: 35225535
8.
Dissection and Immunohistochemistry of the Drosophila Adult Leg to Detect Changes at the Neuromuscular Junction for an Identified Motor Neuron. Stilwell G, Agudelo A.
J Vis Exp. 2022 Feb 12;(180). doi: 10.3791/62844.
PMID: 35225252
9.
A Smartphone Application as an Exploratory Endpoint in a Phase 3 Parkinson’s Disease Clinical Trial: A Pilot Study. Page A, Yung N, Auinger P, Venuto C, Glidden A, Macklin E, Omberg L, Schwarzschild MA, Dorsey ER.
Digit Biomark. 2022 Jan 10;6(1):1-8. doi: 10.1159/000521232. eCollection 2022.
PMID: 35224425 Free PMC article.
10.
The association between dairy intake and migraine odds among pediatrics and adolescents: A case-control study. Ariyanfar S, Razeghi Jahromi S, Rezaeimanesh N, Togha M, Ghorbani Z, Khadem E, Noormohammadi M, Torkan Z.
Iran J Child Neurol. 2022 Winter;16(1):105-122. doi: 10.22037/ijcn.v15i4.3062. Epub 2022 Jan 1.
PMID: 35222662
11.
Advance Care Planning in Neurodegenerative Disorders: A Scoping Review. Giordano A, De Panfilis L, Perin M, Servidio L, Cascioli M, Grasso MG, Lugaresi A, Pucci E, Veronese S, Solari A.
Int J Environ Res Public Health. 2022 Jan 12;19(2):803. doi: 10.3390/ijerph19020803.
PMID: 35055625 Free PMC article. Review.
12.
Genes, brain dynamics and art: the genetic underpinnings of creativity in dancing, musicality and visual arts. Sotiropoulos MG, Anagnostouli M.
J Integr Neurosci. 2021 Dec 30;20(4):1095-1104. doi: 10.31083/j.jin2004110.
PMID: 34997732 Review.
13.
Microglia Do Not Restrict SARS-CoV-2 Replication following Infection of the Central Nervous System of K18-Human ACE2 Transgenic Mice. Olivarria GM, Cheng Y, Furman S, Pachow C, Hohsfield LA, Smith-Geater C, Miramontes R, Wu J, Burns MS, Tsourmas KI, Stocksdale J, Manlapaz C, Yong WH, Teijaro J, Edwards R, Green KN, Thompson LM, Lane TE.
J Virol. 2022 Feb 23;96(4):e0196921. doi: 10.1128/jvi.01969-21. Epub 2021 Dec 22.
PMID: 34935438
14.
Interleukin-35: Structure, Function and Its Impact on Immune-Related Diseases. Ye C, Yano H, Workman CJ, Vignali DAA.
J Interferon Cytokine Res. 2021 Nov;41(11):391-406. doi: 10.1089/jir.2021.0147.
PMID: 34788131 Review.
15.
Aseptic Neutrophilic Meningitis With Hypoglycorrhachia Following a Single Ocrelizumab Infusion. Cicero S, Rissanen E, Carter K, Nguyen H, Petit R, Ellerin TB, Dhillon R, Singhal T.
Neurol Neuroimmunol Neuroinflamm. 2021 Jul 1;8(5):e1025. doi: 10.1212/NXI.0000000000001025. Print 2021 Sep.
PMID: 34210799 Free PMC article. No abstract available.
1.
Centrally-located transverse myelitis would facilitate the differentiation of NMOSD and MOG-AD from MS. Etemadifar M, Salari M, Etemadifar MR, Sabeti F, Fateh ST, Aminzade Z.
Mult Scler Relat Disord. 2022 Feb 12;60:103664. doi: 10.1016/j.msard.2022.103664. Online ahead of print.
PMID: 35219242
2.
Towards individualized monitoring of cognition in multiple sclerosis in the digital era: A one-year cohort study. Ka-Hoo L, Ioan B, Oirschot Pim V, Graaf Frank D, Hans W, Eva S, Bernard U, T H, Joep K, Groot Vincent D.
Mult Scler Relat Disord. 2022 Feb 19;60:103692. doi: 10.1016/j.msard.2022.103692. Online ahead of print.
PMID: 35219240
3.
Prospective associations of better quality of the diet with improved quality of life over 7.5 years in people with multiple sclerosis. Simpson-Yap S, Nag N, Probst Y, Reece JC, Jelinek GA, Neate S.
Mult Scler Relat Disord. 2022 Feb 21;60:103710. doi: 10.1016/j.msard.2022.103710. Online ahead of print.
PMID: 35219239
4.
Microglia as therapeutic targets for central nervous system remyelination. Mahmood A, Miron VE.
Curr Opin Pharmacol. 2022 Feb 23;63:102188. doi: 10.1016/j.coph.2022.102188. Online ahead of print.
PMID: 35219055 Review.
5.
Disease-modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta-analysis. Valizadeh A, Fattahi MR, Sadeghi M, Saghab Torbati M, Sahraian MA, Azimi AR.
CNS Neurosci Ther. 2022 Feb 25. doi: 10.1111/cns.13815. Online ahead of print.
PMID: 35218155
6.
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal. Rollot F, Couturier J, Casey R, Wiertlewski S, Debouverie M, Pelletier J, De Sèze J, Labauge P, Ruet A, Thouvenot E, Ciron J, Berger E, Gout O, Clavelou P, Stankoff B, Casez O, Bourre B, Zephir H, Moreau T, Lebrun-Frenay C, Maillart E, Edan G, Neau JP, Montcuquet A, Cabre P, Camdessanché JP, Defer G, Nasr HB, Maurousset A, Hankiewicz K, Pottier C, Leray E, Vukusic S, Laplaud DA.
Neurotherapeutics. 2022 Feb 25. doi: 10.1007/s13311-022-01202-1. Online ahead of print.
PMID: 35217934
7.
Salt-inducible kinases inhibitor HG-9-91-01 targets RIPK3 kinase activity to alleviate necroptosis-mediated inflammatory injury. Huang D, Chen P, Huang G, Sun H, Luo X, He C, Chen F, Wang Y, Zeng C, Su L, Zeng X, Lu J, Li S, Huang D, Gao H, Cao M.
Cell Death Dis. 2022 Feb 25;13(2):188. doi: 10.1038/s41419-022-04633-y.
PMID: 35217652
8.
Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis. Müller J, Sinnecker T, Wendebourg MJ, Schläger R, Kuhle J, Schädelin S, Benkert P, Derfuss T, Cattin P, Jud C, Spiess F, Amann M, Lincke T, Barakovic M, Cagol A, Tsagkas C, Parmar K, Pröbstel AK, Reimann S, Asseyer S, Duchow A, Brandt A, Ruprecht K, Hadjikhani N, Fukumoto S, Watanabe M, Masaki K, Matsushita T, Isobe N, Kira JI, Kappos L, Würfel J, Granziera C, Paul F, Yaldizli Ö.
Neurol Neuroimmunol Neuroinflamm. 2022 Feb 25;9(3):e1147. doi: 10.1212/NXI.0000000000001147. Print 2022 May.
PMID: 35217580
9.
Cortical and subcortical changes in resting-state neuronal activity and connectivity in early symptomatic ALS and advanced frontotemporal dementia. Govaarts R, Beeldman E, Fraschini M, Griffa A, Engels MMA, van Es MA, Veldink JH, van den Berg LH, van der Kooi AJ, Pijnenburg YAL, de Visser M, Stam CJ, Raaphorst J, Hillebrand A.
Neuroimage Clin. 2022 Feb 12;34:102965. doi: 10.1016/j.nicl.2022.102965. Online ahead of print.
PMID: 35217500
10.
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents. Mariottini A, Forci B, Gualdani E, Romoli M, Repice AM, Barilaro A, Mechi C, Massacesi L, Francesconi P.
Mult Scler Relat Disord. 2022 Feb 9;60:103679. doi: 10.1016/j.msard.2022.103679. Online ahead of print.
PMID: 35217486
11.
Temporal Incidence and Prevalence Trends of Multiple Sclerosis in Markazi Province, Iran. Faraji F, Ahmadi F, Mohaghegh P, Talaie A.
Mult Scler Relat Disord. 2022 Feb 22;60:103691. doi: 10.1016/j.msard.2022.103691. Online ahead of print.
PMID: 35217485
12.
Novel oxindole compounds inhibit the aggregation of amyloidogenic proteins associated with neurodegenerative diseases. Kimura S, Kamishina H, Hirata Y, Furuta K, Furukawa Y, Yamato O, Maeda S, Kamatari YO.
Biochim Biophys Acta Gen Subj. 2022 Feb 22:130114. doi: 10.1016/j.bbagen.2022.130114. Online ahead of print.
PMID: 35217127
13.
Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD. Dinoto A, Sechi E, Ferrari S, Gajofatto A, Orlandi R, Solla P, Maccabeo A, Maniscalco GT, Andreone V, Sartori A, Manganotti P, Rasia S, Capra R, Mancinelli CR, Mariotto S.
Mult Scler Relat Disord. 2022 Feb;58:103424. doi: 10.1016/j.msard.2021.103424. Epub 2021 Nov 22.
PMID: 35216793
14.
Spatial navigation performance in people with multiple sclerosis-a large-scale online study. van der Ham IJM, Koutzmpi V, van der Kuil MNA, van der Hiele K.
Mult Scler Relat Disord. 2022 Feb;58:103423. doi: 10.1016/j.msard.2021.103423. Epub 2021 Nov 23.
PMID: 35216792
15.
Molluscum contagiosum in the setting of Fingolimod: The experience at one institution. Schneider S, Do D, Fuller R, Berger JR.
Mult Scler Relat Disord. 2022 Feb;58:103419. doi: 10.1016/j.msard.2021.103419. Epub 2021 Nov 22.
PMID: 35216791
16.
Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy. Giossi R, Consonni A, Torri Clerici V, Zito A, Rigoni E, Antozzi C, Brambilla L, Crisafulli SG, Bellino A, Frangiamore R, Bonanno S, Vanoli F, Ciusani E, Corsini E, Andreetta F, Baggi F, Tramacere I, Mantegazza R, Conte A, Bergamaschi R, Confalonieri P.
Mult Scler Relat Disord. 2022 Feb;58:103415. doi: 10.1016/j.msard.2021.103415. Epub 2021 Nov 22.
PMID: 35216790
17.
Response to treatment in NMOSD: the Australasian experience. Clarke L, Bukhari W, O’Gorman CM, Khalilidehkordi E, Arnett S, Woodhall M, Prain KM, Parratt JDE, Barnett MH, Marriott MP, McCombe PA, Sutton I, Boggild M, Brownlee W, Carroll WM, Hodgkinson S, Macdonell RAL, Mason DF, Pereira J, Slee M, Das C, Henderson APD, Kermode AG, Lechner-Scott J; ANZ NMO Collaboration, Waters P, Sun J, Broadley SA.
Mult Scler Relat Disord. 2022 Feb;58:103408. doi: 10.1016/j.msard.2021.103408. Epub 2021 Nov 21.
PMID: 35216788
18.
Mechanisms of myelin repair, MRI techniques and therapeutic opportunities in multiple sclerosis. Sommer RC, Hata J, Rimkus CM, Klein da Costa B, Nakahara J, Sato DK.
Mult Scler Relat Disord. 2022 Feb;58:103407. doi: 10.1016/j.msard.2021.103407. Epub 2021 Nov 16.
PMID: 35216787 Review.
19.
Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study. Saposnik G, Andhavarapu S, Fernández Ó, Kim HJ, Wiendl H, Foss M, Zuo F, Havrdová EK, Celius E, Caceres F, Magyari M, Bermel R, Costa A, Terzaghi M, Kalincik T, Popescu V, Amato MP, Montalban X, Oh J.
Mult Scler Relat Disord. 2022 Feb;58:103404. doi: 10.1016/j.msard.2021.103404. Epub 2021 Nov 16.
PMID: 35216786
20.
Body size perceptions & diet modification in youth with multiple sclerosis. Woolbright E, Koshiya H, Brenton JN.
Mult Scler Relat Disord. 2022 Feb;58:103402. doi: 10.1016/j.msard.2021.103402. Epub 2021 Nov 16.
PMID: 35216785 Free PMC article.
21.
Clinical and demographic characteristics of male MS patients included in the national registry-RelevarEM. Does sex or phenotype make the difference in the association with poor prognosis? Luetic GG, Menichini ML, Vrech C, Pappolla A, Patrucco L, Cristiano E, Marrodán M, Ysrraelit MC, Fiol M, Correale J, Cohen L, Alonso R, Silva B, Casas M, Garcea O, Deri N, Burgos M, Liwacki S, Tkachuk V, Barboza A, Piedrabuena R, Blaya P, Steinberg J, Martínez A, Carrá A, Tavolini D, López P, Knorre E, Nofal P, Volman G, Carnero Contentti E, Pinheiro AA, Leguizamon F, Silva E, Hryb J, Balbuena ME, Zanga G, Kohler M, Chertcoff A, Lazaro L, Tizio S, Mainela C, Reich E, Recchia L, Blanche J, Marcilla MP, Fracaro ME, Sgrilli G, Divi P, Jacobo M, Cabrera M, Pagani Cassara F, Sinay V, Curbelo C, Míguez J, Coppola M, Liguori NF, Martos I, Pettinicchi JP, Viglione JP, José G, Bestoso S, Manzi R, Vázquez G, Nadur D, Martínez C, Serena MA, Rojas JI.
Mult Scler Relat Disord. 2022 Feb;58:103401. doi: 10.1016/j.msard.2021.103401. Epub 2021 Nov 17.
PMID: 35216784
22.
Feasibility and efficacy of home-based neurofunctional exercise vs. resistance exercise programs for ambulatory disability of multiple sclerosis patients with cognitive impairment. Mardaniyan Ghahfarrokhi M, Banitalebi E, Faramarzi M, Motl R.
Mult Scler Relat Disord. 2022 Feb;58:103400. doi: 10.1016/j.msard.2021.103400. Epub 2021 Nov 13.
PMID: 35216783
23.
Measuring productivity loss in early relapsing-remitting multiple sclerosis. Sainz de la Maza S, Maurino J, Borges M, Martín-Martínez J, Sotoca J, Alonso A, Caminero AB, Borrega L, Sánchez-Menoyo JL, Barrero-Hernández FJ, Calles C, Brieva L, Blasco MR, García-Soto JD, Campo-Amigo MD, Navarro-Cantó L, Agüera E, Garcés M, Carmona O, Gabaldón-Torres L, Forero L, Hervás M, de Alda LR, Gómez-Ballesteros R, Castillo-Triviño T.
Mult Scler Relat Disord. 2022 Feb;58:103398. doi: 10.1016/j.msard.2021.103398. Epub 2021 Nov 10.
PMID: 35216781
24.
Validation of the fatigue severity scale in Croatian population of patients with multiple sclerosis disease: Factor structure, internal consistency, and correlates. Jerković A, Proroković A, Matijaca M, Katić AĆ, Košta V, Mihalj M, Dolić K, Đogaš Z, Vidaković MR.
Mult Scler Relat Disord. 2022 Feb;58:103397. doi: 10.1016/j.msard.2021.103397. Epub 2021 Nov 10.
PMID: 35216780
25.
Quantification of normal-appearing white matter damage in early relapse-onset multiple sclerosis through neurite orientation dispersion and density imaging. Margoni M, Villani U, Silvestri E, Franciotta S, Anglani MG, Causin F, Rinaldi F, Perini P, Bertoldo A, Gallo P.
Mult Scler Relat Disord. 2022 Feb;58:103396. doi: 10.1016/j.msard.2021.103396. Epub 2021 Nov 10.
PMID: 35216779
26.
The effects of HMG-CoA reductase inhibitors on disease activity in multiple sclerosis: A systematic review and meta-analysis. Stefanou MI, Palaiodimou L, Katsanos AH, Milionis H, Kosmidou M, Lambadiari V, Halvatsiotis P, Ferentinos P, Andreadou E, Marinos G, Theodorou A, Tzartos JS, Voumvourakis K, Tsivgoulis G, Giannopoulos S.
Mult Scler Relat Disord. 2022 Feb;58:103395. doi: 10.1016/j.msard.2021.103395. Epub 2021 Nov 10.
PMID: 35216778
27.
A serial mediation model of gratitude on life satisfaction in people with multiple sclerosis: The intermediary role of perceived stress and mental health symptoms. Lee B.
Mult Scler Relat Disord. 2022 Feb;58:103421. doi: 10.1016/j.msard.2021.103421. Epub 2021 Nov 22.
PMID: 35216777
28.
Short quality of life scale: A cross-cultural validation in Iranian patients with multiple sclerosis. Zarrabi-Ajami S, Zamanian H, Amini-Tehrani M, Farhadidanaloo Z, Razavi RJ, Abbasi A, Darbandi S, Chenari P.
Mult Scler Relat Disord. 2022 Feb;58:103411. doi: 10.1016/j.msard.2021.103411. Epub 2021 Nov 17.
PMID: 35216776
29.
Subjective versus objective performance in people with multiple sclerosis using the MSReactor computerised cognitive tests. Merlo D, Kalincik T, Zhu C, Gresle M, Lechner-Scott J, Kilpatrick T, Barnett M, Taylor B, Buzzard K, Darby D, Butzkueven H, van der Walt A.
Mult Scler Relat Disord. 2022 Feb;58:103393. doi: 10.1016/j.msard.2021.103393. Epub 2021 Nov 10.
PMID: 35216774
30.
Percutaneous posterior tibial nerve stimulation (PTNS) for lower urinary tract symptoms (LUTSs) treatment in patients with multiple sclerosis (MS): A systematic review and meta-analysis. Guitynavard F, Mirmosayyeb O, Razavi ERV, Hosseini M, Hosseinabadi AM, Ghajarzadeh M, Azadvari M.
Mult Scler Relat Disord. 2022 Feb;58:103392. doi: 10.1016/j.msard.2021.103392. Epub 2021 Nov 10.
PMID: 35216773 Review.
31.
Promising Treatment for Multiple Sclerosis: Mitochondrial Transplantation. Picone P, Nuzzo D.
Int J Mol Sci. 2022 Feb 17;23(4):2245. doi: 10.3390/ijms23042245.
PMID: 35216361
32.
The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice. Nowicka N, Szymańska K, Juranek J, Zglejc-Waszak K, Korytko A, Załęcki M, Chmielewska-Krzesińska M, Wąsowicz K, Wojtkiewicz J.
Int J Mol Sci. 2022 Feb 16;23(4):2184. doi: 10.3390/ijms23042184.
PMID: 35216298
33.
Effect of Multiple Sclerosis Cerebrospinal Fluid and Oligodendroglia Cell Line Environment on Human Wharton’s Jelly Mesenchymal Stem Cells Secretome. Salwierak-Głośna K, Piątek P, Domowicz M, Świderek-Matysiak M.
Int J Mol Sci. 2022 Feb 16;23(4):2177. doi: 10.3390/ijms23042177.
PMID: 35216294
34.
Interferon-β Activity Is Affected by S100B Protein. Kazakov AS, Sofin AD, Avkhacheva NV, Deryusheva EI, Rastrygina VA, Permyakova ME, Uversky VN, Permyakov EA, Permyakov SE.
Int J Mol Sci. 2022 Feb 11;23(4):1997. doi: 10.3390/ijms23041997.
PMID: 35216109
35.
Viral Proteins with PxxP and PY Motifs May Play a Role in Multiple Sclerosis. Pi KS, Sang Y, Straus SK.
Viruses. 2022 Jan 28;14(2):281. doi: 10.3390/v14020281.
PMID: 35215874 Review.
36.
SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot. Achtnichts L, Ovchinnikov A, Jakopp B, Oberle M, Nedeltchev K, Fux CA, Sellner J, Findling O.
Vaccines (Basel). 2022 Feb 21;10(2):341. doi: 10.3390/vaccines10020341.
PMID: 35214799
37.
Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination. Golshani M, Hrdý J.
Vaccines (Basel). 2022 Feb 11;10(2):279. doi: 10.3390/vaccines10020279.
PMID: 35214735 Review.
38.
Manipulating Macrophage/Microglia Polarization to Treat Glioblastoma or Multiple Sclerosis. Kuntzel T, Bagnard D.
Pharmaceutics. 2022 Feb 1;14(2):344. doi: 10.3390/pharmaceutics14020344.
PMID: 35214076 Review.
1.
Impact of disease-modifying therapies on humoral and cellular immune-responses following SARS-CoV-2 vaccination in MS patients. Trümpelmann S, Schulte-Mecklenbeck A, Steinberg OV, Wirth T, Fobker M, Lohmann L, Lünemann JD, Wiendl H, Gross CC, Klotz L.
Clin Transl Sci. 2022 Feb 25. doi: 10.1111/cts.13256. Online ahead of print.
PMID: 35213793
2.
Neurology’s vital role in preventing unnecessary and potentially harmful pediatric studies. Rose K, Ettienne EB, Grant-Kels JM, Striano P, Neubauer D, Tanjinatus O.
Expert Rev Neurother. 2022 Feb 25. doi: 10.1080/14737175.2022.2045953. Online ahead of print.
PMID: 35213279
3.
Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab. Madelon N, Heikkilä N, Sabater Royo I, Fontannaz P, Breville G, Lauper K, Goldstein R, Grifoni A, Sette A, Siegrist CA, Finckh A, Lalive PH, Didierlaurent AM, Eberhardt CS.
JAMA Neurol. 2022 Feb 25. doi: 10.1001/jamaneurol.2022.0245. Online ahead of print.
PMID: 35212717
4.
Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report. Sugawara E, Sato T, Amasaki Y, Katsumata K.
Medicine (Baltimore). 2022 Feb 25;101(8):e28941. doi: 10.1097/MD.0000000000028941.
PMID: 35212301
5.
Newly diagnosed multiple sclerosis in a patient with ocular myasthenia gravis: A case report. Bong JB, Lee MA, Kang HG.
Medicine (Baltimore). 2022 Feb 25;101(8):e28887. doi: 10.1097/MD.0000000000028887.
PMID: 35212290
6.
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study. Wray S, Then Bergh F, Wundes A, Arnold DL, Drulovic J, Jasinska E, Bowen JD, Negroski D, Naismith RT, Hunter SF, Gudesblatt M, Chen H, Lyons J, Shankar SL, Kapadia S, Mendoza JP, Singer BA.
Adv Ther. 2022 Feb 24. doi: 10.1007/s12325-022-02068-7. Online ahead of print.
PMID: 35211872
7.
wSDTNBI: a novel network-based inference method for virtual screening. Wu Z, Ma H, Liu Z, Zheng L, Yu Z, Cao S, Fang W, Wu L, Li W, Liu G, Huang J, Tang Y.
Chem Sci. 2021 Dec 21;13(4):1060-1079. doi: 10.1039/d1sc05613a. eCollection 2022 Jan 26.
PMID: 35211272 Free PMC article.
8.
A Final Frontier in Environment-Genome Interactions? Integrated, Multi-Omic Approaches to Predictions of Non-Communicable Disease Risk. Noble AJ, Purcell RV, Adams AT, Lam YK, Ring PM, Anderson JR, Osborne AJ.
Front Genet. 2022 Feb 8;13:831866. doi: 10.3389/fgene.2022.831866. eCollection 2022.
PMID: 35211161 Free PMC article. Review.
9.
Astrocytes and Inflammatory T Helper Cells: A Dangerous Liaison in Multiple Sclerosis. Kunkl M, Amormino C, Tedeschi V, Fiorillo MT, Tuosto L.
Front Immunol. 2022 Feb 8;13:824411. doi: 10.3389/fimmu.2022.824411. eCollection 2022.
PMID: 35211120 Free PMC article. Review.
10.
Predicting Multiple Sclerosis: Challenges and Opportunities. Hone L, Giovannoni G, Dobson R, Jacobs BM.
Front Neurol. 2022 Feb 8;12:761973. doi: 10.3389/fneur.2021.761973. eCollection 2021.
PMID: 35211072 Free PMC article. Review.
11.
Multimodal Evoked Potentials as Potential Biomarkers of Disease Activity in Patients With Clinically Isolated Syndrome. Dziadkowiak E, Wieczorek M, Zagrajek M, Chojdak-Łukasiewicz J, Gruszka E, Budrewicz S, Pokryszko-Dragan A.
Front Neurol. 2022 Feb 8;12:678035. doi: 10.3389/fneur.2021.678035. eCollection 2021.
PMID: 35211070 Free PMC article.
12.
Quantification of Neurite Degeneration with Enhanced Accuracy and Efficiency in an In Vitro Model of Parkinson’s Disease. Clements RT, Fuller LE, Kraemer KR, Radomski SA, Hunter-Chang S, Hall WC, Kalantar AA, Kraemer BR.
eNeuro. 2022 Feb 22:ENEURO.0327-21.2022. doi: 10.1523/ENEURO.0327-21.2022. Online ahead of print.
PMID: 35210286
13.
Vincamine Modulates the Effect of Pantoprazole in Renal Ischemia/Reperfusion Injury by Attenuating MAPK and Apoptosis Signaling Pathways. Fawzy MA, Maher SA, El-Rehany MA, Welson NN, Albezrah NKA, Batiha GE, Fathy M.
Molecules. 2022 Feb 18;27(4):1383. doi: 10.3390/molecules27041383.
PMID: 35209172
14.
Muscle Quality of Knee Extensors Based on Several Types of Force in Multiple Sclerosis Patients with Varying Degrees of Disability. Portilla-Cueto K, Medina-Pérez C, Romero-Pérez EM, Núñez-Othón G, Horta-Gim MA, de Paz JA.
Medicina (Kaunas). 2022 Feb 19;58(2):316. doi: 10.3390/medicina58020316.
PMID: 35208639
15.
TDP-43 Proteinopathy Causes Broad Metabolic Alterations including TCA Cycle Intermediates and Dopamine Levels in Drosophila Models of ALS. Loganathan S, Wilson BA, Carey SB, Manzo E, Joardar A, Ugur B, Zarnescu DC.
Metabolites. 2022 Jan 21;12(2):101. doi: 10.3390/metabo12020101.
PMID: 35208176
16.
Increased Complement Activation in Systemic Sclerosis Patients with Skin and Lung Fibrosis. Pellicano C, Miglionico M, Romaggioli L, Colalillo A, Vantaggio L, Napodano C, Callà C, Gulli F, Marino M, Basile U, Rosato E.
J Pers Med. 2022 Feb 15;12(2):284. doi: 10.3390/jpm12020284.
PMID: 35207772
17.
Plasma Protein Levels Analysis in Multiple Sclerosis Sardinian Families Identified C9 and CYP24A1 as Candidate Biomarkers. Nova A, Fazia T, Beecham A, Saddi V, Piras M, McCauley JL, Berzuini C, Bernardinelli L.
Life (Basel). 2022 Jan 20;12(2):151. doi: 10.3390/life12020151.
PMID: 35207439
18.
Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature. Patti F, Chisari CG, Toscano S, Arena S, Finocchiaro C, Cimino V, Milone G.
J Clin Med. 2022 Feb 11;11(4):942. doi: 10.3390/jcm11040942.
PMID: 35207216 Review.
19.
Pain-Related Coping Behavior in ALS: The Interplay between Maladaptive Coping, the Patient’s Affective State and Pain. Schlichte I, Petri S, Dengler R, Meyer T, Haghikia A, Vielhaber S, Vogt S.
J Clin Med. 2022 Feb 11;11(4):944. doi: 10.3390/jcm11040944.
PMID: 35207215
20.
Acid-Sensing Ion Channels in Glial Cells. Cegielski V, Chakrabarty R, Ding S, Wacker MJ, Monaghan-Nichols P, Chu XP.
Membranes (Basel). 2022 Jan 20;12(2):119. doi: 10.3390/membranes12020119.
PMID: 35207041 Review.
21.
Acid-Sensing Ion Channel 2: Function and Modulation. Sivils A, Yang F, Wang JQ, Chu XP.
Membranes (Basel). 2022 Jan 19;12(2):113. doi: 10.3390/membranes12020113.
PMID: 35207035 Review.
22.
Adherence to Therapy in Patients with Multiple Sclerosis-Review. Kołtuniuk A, Chojdak-Łukasiewicz J.
Int J Environ Res Public Health. 2022 Feb 15;19(4):2203. doi: 10.3390/ijerph19042203.
PMID: 35206387 Review.
23.
The BDNF Val66Met Polymorphism (rs6265) Modulates Inflammation and Neurodegeneration in the Early Phases of Multiple Sclerosis. Dolcetti E, Bruno A, Azzolini F, Gilio L, Moscatelli A, De Vito F, Pavone L, Iezzi E, Gambardella S, Giardina E, Ferese R, Buttari F, Rizzo FR, Furlan R, Finardi A, Musella A, Mandolesi G, Guadalupi L, Centonze D, Stampanoni Bassi M.
Genes (Basel). 2022 Feb 10;13(2):332. doi: 10.3390/genes13020332.
PMID: 35205376
24.
Sexual Dimorphism in Extracellular Matrix Composition and Viscoelasticity of the Healthy and Inflamed Mouse Brain. Batzdorf CS, Morr AS, Bertalan G, Sack I, Silva RV, Infante-Duarte C.
Biology (Basel). 2022 Jan 31;11(2):230. doi: 10.3390/biology11020230.
PMID: 35205095
25.
Are Cell-Based Therapies Safe and Effective in the Treatment of Neurodegenerative Diseases? A Systematic Review with Meta-Analysis. Van den Bos J, Ouaamari YE, Wouters K, Cools N, Wens I.
Biomolecules. 2022 Feb 21;12(2):340. doi: 10.3390/biom12020340.
PMID: 35204840 Review.
26.
Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis. Azzolini F, Gilio L, Pavone L, Iezzi E, Dolcetti E, Bruno A, Buttari F, Musella A, Mandolesi G, Guadalupi L, Furlan R, Finardi A, Micillo T, Carbone F, Matarese G, Centonze D, Stampanoni Bassi M.
Biomolecules. 2022 Jan 27;12(2):222. doi: 10.3390/biom12020222.
PMID: 35204724
27.
Cerebrospinal Fluid α-Calcitonin Gene-Related Peptide: A Comparison between Alzheimer’s Disease and Multiple Sclerosis. Papiri G, Vignini A, Capriotti L, Verdenelli P, Alia S, Di Paolo A, Fiori C, Baldinelli S, Silvestrini M, Luzzi S.
Biomolecules. 2022 Jan 24;12(2):199. doi: 10.3390/biom12020199.
PMID: 35204700
28.
Editorial of Special Issue “Multiple Sclerosis: From Diagnostic Biomarkers to Imaging and Clinical Predictors”. Jakimovski D, Zivadinov R.
Diagnostics (Basel). 2022 Feb 13;12(2):482. doi: 10.3390/diagnostics12020482.
PMID: 35204573
29.
Magnetic Resonance Imaging as a Prognostic Disability Marker in Clinically Isolated Syndrome and Multiple Sclerosis: A Systematic Review and Meta-Analysis. AlTokhis AI, AlAmrani A, Alotaibi A, Podlasek A, Constantinescu CS.
Diagnostics (Basel). 2022 Jan 21;12(2):270. doi: 10.3390/diagnostics12020270.
PMID: 35204361 Review.
30.
Lesion Volume Quantification Using Two Convolutional Neural Networks in MRIs of Multiple Sclerosis Patients. de Oliveira M, Piacenti-Silva M, da Rocha FCG, Santos JM, Cardoso JDS, Lisboa-Filho PN.
Diagnostics (Basel). 2022 Jan 18;12(2):230. doi: 10.3390/diagnostics12020230.
PMID: 35204321
31.
Intensive Neurorehabilitation and Gait Improvement in Progressive Multiple Sclerosis: Clinical, Kinematic and Electromyographic Analysis. Huang SC, Guerrieri S, Dalla Costa G, Pisa M, Leccabue G, Gregoris L, Comi G, Leocani L.
Brain Sci. 2022 Feb 12;12(2):258. doi: 10.3390/brainsci12020258.
PMID: 35204021
32.
Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study. Butzkueven H, Giacomini PS, Cohan S, Ziemssen T, Sienkiewicz D, Zhang Y, Geissbühler Y, Silva D, Tomic D, Kropshofer H, Trojano M.
Brain Sci. 2022 Feb 4;12(2):215. doi: 10.3390/brainsci12020215.
PMID: 35203978
33.
Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype. Brochet B, Clavelou P, Defer G, De Seze J, Louapre C, Magnin E, Ruet A, Thomas-Anterion C, Vermersch P.
Brain Sci. 2022 Jan 29;12(2):183. doi: 10.3390/brainsci12020183.
PMID: 35203948 Review.
34.
Olfactory Dysfunction, Headache, and Mental Clouding in Adults with Long-COVID-19: What Is the Link between Cognition and Olfaction? A Cross-Sectional Study. Di Stadio A, Brenner MJ, De Luca P, Albanese M, D’Ascanio L, Ralli M, Roccamatisi D, Cingolani C, Vitelli F, Camaioni A, Di Girolamo S, Bernitsas E.
Brain Sci. 2022 Jan 24;12(2):154. doi: 10.3390/brainsci12020154.
PMID: 35203918
35.
Qualitative and Quantitative Comparison of Hippocampal Volumetric Software Applications: Do All Roads Lead to Rome? Mangesius S, Haider L, Lenhart L, Steiger R, Prados Carrasco F, Scherfler C, Gizewski ER.
Biomedicines. 2022 Feb 12;10(2):432. doi: 10.3390/biomedicines10020432.
PMID: 35203641
36.
Epstein-Barr Virus Load Correlates with Multiple Sclerosis-Associated Retrovirus Envelope Expression. Pérez-Pérez S, Domínguez-Mozo MI, García-Martínez MÁ, Ballester-González R, Nieto-Gañán I, Arroyo R, Alvarez-Lafuente R.
Biomedicines. 2022 Feb 5;10(2):387. doi: 10.3390/biomedicines10020387.
PMID: 35203596
37.
Regulatory Cells in Multiple Sclerosis: From Blood to Brain. Calahorra L, Camacho-Toledano C, Serrano-Regal MP, Ortega MC, Clemente D.
Biomedicines. 2022 Feb 1;10(2):335. doi: 10.3390/biomedicines10020335.
PMID: 35203544 Review.
38.
Are Neurophysiological Biomarkers Able to Discriminate Multiple Sclerosis Clinical Subtypes? Belvisi D, Tartaglia M, Borriello G, Baione V, Crisafulli SG, Zuccoli V, Leodori G, Ianniello A, Pasqua G, Pantano P, Berardelli A, Pozzilli C, Conte A.
Biomedicines. 2022 Jan 21;10(2):231. doi: 10.3390/biomedicines10020231.
PMID: 35203440
39.
L-Arginine Depletion Improves Spinal Cord Injury via Immunomodulation and Nitric Oxide Reduction. Erens C, Van Broeckhoven J, Hoeks C, Schabbauer G, Cheng PN, Chen L, Hellings N, Broux B, Lemmens S, Hendrix S.
Biomedicines. 2022 Jan 18;10(2):205. doi: 10.3390/biomedicines10020205.
PMID: 35203413
40.
The Modulatory Effects of DMF on Microglia in Aged Mice Are Sex-Specific. Mela V, Sayd Gaban A, O’Neill E, Bechet S, Walsh A, Lynch MA.
Cells. 2022 Feb 18;11(4):729. doi: 10.3390/cells11040729.
PMID: 35203379
41.
Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8). Basole CP, Nguyen RK, Lamothe K, Billis P, Fujiwara M, Vang AG, Clark RB, Epstein PM, Brocke S.
Cells. 2022 Feb 14;11(4):660. doi: 10.3390/cells11040660.
PMID: 35203312
1.
T1/T2-weighted ratio in multiple sclerosis: A longitudinal study with clinical associations. Boaventura M, Sastre-Garriga J, Garcia-Vidal A, Vidal-Jordana A, Quartana D, Carvajal R, Auger C, Alberich M, Tintoré M, Rovira À, Montalban X, Pareto D.
Neuroimage Clin. 2022 Feb 16;34:102967. doi: 10.1016/j.nicl.2022.102967. Online ahead of print.
PMID: 35202997
2.
A multiple sclerosis patient-oriented multiomics analysis tells us where to go next: Commentary for: “Alterations of host-gut microbiome interactions in multiple sclerosis”. Yamamura T, Takewaki D.
EBioMedicine. 2022 Feb 21;77:103870. doi: 10.1016/j.ebiom.2022.103870. Online ahead of print.
PMID: 35202903 No abstract available.
3.
Monitoring autoimmune diseases by bioelectrochemical detection of autoantibodies. Application to the determination of anti-myelin basic protein autoantibodies in serum of multiple sclerosis patients. Guerrero S, Sánchez-Tirado E, Agüí L, González-Cortés A, Yáñez-Sedeño P, Pingarrón JM.
Talanta. 2022 Feb 18;243:123304. doi: 10.1016/j.talanta.2022.123304. Online ahead of print.
PMID: 35202838
4.
A Novel MRI-Based Quantitative Water Content Atlas of the Human Brain. Shah NJ, Abbas Z, Ridder D, Zimmermann M, Oros-Peusquens AM.
Neuroimage. 2022 Feb 21:119014. doi: 10.1016/j.neuroimage.2022.119014. Online ahead of print.
PMID: 35202813
5.
Diverse injury responses of human oligodendrocyte to mediators implicated in multiple sclerosis. Pernin F, Luo J, Cui QL, Blain M, Fernandes MGF, Yaqubi M, Srour M, Hall J, Dudley R, Jamann H, Larochelle C, Zandee SEJ, Prat A, Stratton JA, Kennedy TE, Antel JP.
Brain. 2022 Feb 24:awac075. doi: 10.1093/brain/awac075. Online ahead of print.
PMID: 35202462
6.
Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis. Etemadifar M, Abhari AP, Nouri H, Sigari AA, Piran Daliyeh SM, Maracy MR, Salari M, Maleki S, Sedaghat N.
Hum Vaccin Immunother. 2022 Feb 24:1-6. doi: 10.1080/21645515.2022.2041945. Online ahead of print.
PMID: 35201963
7.
Cervical vestibular evoked myogenic potentials and video head impulse test studies: alternative methods for detecting brainstem involvement in multiple sclerosis. Eğilmez OK, Tunç A, Yılmaz MS, Şahiner BG, Koçoğlu M, Eryılmaz HA, Güven M.
Acta Otolaryngol. 2022 Feb 24:1-7. doi: 10.1080/00016489.2022.2039759. Online ahead of print.
PMID: 35200078
8.
Coenzyme Q10 effects in neurological diseases. Rauchová H.
Physiol Res. 2021 Dec 30;70(Suppl4):S683-S714.
PMID: 35199552
9.
Mdivi-1: a promising drug and its underlying mechanisms in the treatment of neurodegenerative diseases. Liu X, Song L, Yu J, Huang F, Li Y, Ma C.
Histol Histopathol. 2022 Feb 24:18443. doi: 10.14670/HH-18-443. Online ahead of print.
PMID: 35199329 Review.
10.
Curdlan, a Microbial β-Glucan, Has Contrasting Effects on Autoimmune and Viral Models of Multiple Sclerosis. Sato F, Nakamura Y, Katsuki A, Khadka S, Ahmad I, Omura S, Martinez NE, Tsunoda I.
Front Cell Infect Microbiol. 2022 Feb 7;12:805302. doi: 10.3389/fcimb.2022.805302. eCollection 2022.
PMID: 35198458 Free PMC article.
11.
Multiple Sclerosis Relapse Following COVID-19 Vaccination: A Case Report and Literature Review. Kataria S, Rogers S, Bilal U, Baktashi H, Singh R.
Cureus. 2022 Jan 18;14(1):e21374. doi: 10.7759/cureus.21374. eCollection 2022 Jan.
PMID: 35198286 Free PMC article.
12.
Haematopoietic Stem Cell Transplantation Results in Extensive Remodelling of the Clonal T Cell Repertoire in Multiple Sclerosis. Massey J, Jackson K, Singh M, Hughes B, Withers B, Ford C, Khoo M, Hendrawan K, Zaunders J, Charmeteau-De Muylder B, Cheynier R, Luciani F, Ma D, Moore J, Sutton I.
Front Immunol. 2022 Feb 7;13:798300. doi: 10.3389/fimmu.2022.798300. eCollection 2022.
PMID: 35197974 Free PMC article.
13.
Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients. Boldrini VO, Marques AM, Quintiliano RPS, Moraes AS, Stella CRAV, Longhini ALF, Santos I, Andrade M, Ferrari B, Damasceno A, Carneiro RPD, Brandão CO, Farias AS, Santos LMB.
Front Immunol. 2022 Feb 7;13:750660. doi: 10.3389/fimmu.2022.750660. eCollection 2022.
PMID: 35197967 Free PMC article.
14.
Theoretical and Therapeutic Implications of the Spasticity-Plus Syndrome Model in Multiple Sclerosis. Bruno A, Dolcetti E, Centonze D.
Front Neurol. 2022 Feb 7;12:802918. doi: 10.3389/fneur.2021.802918. eCollection 2021.
PMID: 35197915 Free PMC article.
15.
The Neuroimmunology of Multiple Sclerosis: Fictions and Facts. Pachner AR.
Front Neurol. 2022 Feb 7;12:796378. doi: 10.3389/fneur.2021.796378. eCollection 2021.
PMID: 35197914 Free PMC article. Review.
16.
Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. Vaccarino AL, Beaton D, Black SE, Blier P, Farzan F, Finger E, Foster JA, Freedman M, Frey BN, Gilbert Evans S, Ho K, Javadi M, Kennedy SH, Lam RW, Lang AE, Lasalandra B, Latour S, Masellis M, Milev RV, Müller DJ, Munoz DP, Parikh SV, Placenza F, Rotzinger S, Soares CN, Sparks A, Strother SC, Swartz RH, Tan B, Tartaglia MC, Taylor VH, Theriault E, Turecki G, Uher R, Zinman L, Evans KR.
Front Psychiatry. 2022 Feb 7;13:816465. doi: 10.3389/fpsyt.2022.816465. eCollection 2022.
PMID: 35197877 Free PMC article.
17.
The lung microbiome regulates brain autoimmunity. Hosang L, Canals RC, van der Flier FJ, Hollensteiner J, Daniel R, Flügel A, Odoardi F.
Nature. 2022 Feb 23. doi: 10.1038/s41586-022-04427-4. Online ahead of print.
PMID: 35197636
18.
Teriflunomide shifts the astrocytic bioenergetic profile from oxidative metabolism to glycolysis and attenuates TNFα-induced inflammatory responses. Kabiraj P, Grund EM, Clarkson BDS, Johnson RK, LaFrance-Corey RG, Lucchinetti CF, Howe CL.
Sci Rep. 2022 Feb 23;12(1):3049. doi: 10.1038/s41598-022-07024-7.
PMID: 35197552
19.
B cell-dependent EAE induces visual deficits in the mouse with similarities to human autoimmune demyelinating diseases. Joly S, Mdzomba JB, Rodriguez L, Morin F, Vallières L, Pernet V.
J Neuroinflammation. 2022 Feb 23;19(1):54. doi: 10.1186/s12974-022-02416-y.
PMID: 35197067
20.
Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS. Xiang B, Brier MR, Kanthamneni M, Wen J, Snyder AZ, Yablonskiy DA, Cross AH.
Mult Scler. 2022 Feb 23:13524585211073761. doi: 10.1177/13524585211073761. Online ahead of print.
PMID: 35196933
21.
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, Iacobaeus E, Mycko M, Abboud H, Achiron A, Bellinvia A, Boyko A, Casanova JL, Clifford D, Dobson R, Farez MF, Filippi M, Fitzgerald KC, Fonderico M, Gouider R, Hacohen Y, Hellwig K, Hemmer B, Kappos L, Ladeira F, Lebrun-Frénay C, Louapre C, Magyari M, Mehling M, Oreja-Guevara C, Pandit L, Papeix C, Piehl F, Portaccio E, Ruiz-Camps I, Selmaj K, Simpson-Yap S, Siva A, Sorensen PS, Sormani MP, Trojano M, Vaknin-Dembinsky A, Vukusic S, Weinshenker B, Wiendl H, Winkelmann A, Zuluaga Rodas MI, Tintoré M, Stankoff B.
Mult Scler. 2022 Feb 23:13524585211069068. doi: 10.1177/13524585211069068. Online ahead of print.
PMID: 35196927
22.
Pandemics disable people – the history lesson that policymakers ignore. Spinney L.
Nature. 2022 Feb;602(7897):383-385. doi: 10.1038/d41586-022-00414-x.
PMID: 35173335 No abstract available.
23.
The neuroprotective effects and transdifferentiation of astrocytes into dopaminergic neurons of Ginkgolide K on Parkinson’ disease mice. Miao Q, Chai Z, Song LJ, Wang Q, Song GB, Wang J, Yu JZ, Xiao BG, Ma CG.
J Neuroimmunol. 2022 Mar 15;364:577806. doi: 10.1016/j.jneuroim.2022.577806. Epub 2022 Jan 7.
PMID: 35121334
24.
Natalizumab-induced pneumonitis. Kaninia S, Edey AJ, Maskell NA, Rice CM.
J Neurol. 2022 Mar;269(3):1688-1690. doi: 10.1007/s00415-021-10811-3. Epub 2021 Sep 22.
PMID: 34550470 Free PMC article. No abstract available.
1.
Validation of the Norma Latina neuropsychological assessment battery in individuals with multiple sclerosis in Mexico. Rivera D, Ramos Usuga D, Fuentes Mendoza EM, Aguayo Arelis A, Rabago Barajas BV, Macías Islas MÁ, Krch D, Lequerica AH, Arango-Lasprilla JC.
Mult Scler Relat Disord. 2022 Feb 12;59:103685. doi: 10.1016/j.msard.2022.103685. Online ahead of print.
PMID: 35196609
2.
JAK1 signaling in dendritic cells promotes peripheral tolerance in autoimmunity through PD-L1-mediated regulatory T cell induction. Vogel A, Martin K, Soukup K, Halfmann A, Kerndl M, Brunner JS, Hofmann M, Oberbichler L, Korosec A, Kuttke M, Datler H, Kieler M, Musiejovsky L, Dohnal A, Sharif O, Schabbauer G.
Cell Rep. 2022 Feb 22;38(8):110420. doi: 10.1016/j.celrep.2022.110420.
PMID: 35196494
3.
Hormone therapy and disease activity in Danish women with multiple sclerosis – a population-based cohort study. Kopp TI, Lidegaard Ø, Magyari M.
Eur J Neurol. 2022 Feb 23. doi: 10.1111/ene.15299. Online ahead of print.
PMID: 35196406
4.
Autoimmune disease and interconnections with vitamin D. Fletcher J, Bishop EL, Harrison SR, Swift A, Cooper SC, Dimeloe SK, Raza K, Hewison M.
Endocr Connect. 2022 Feb 1:EC-21-0554. doi: 10.1530/EC-21-0554. Online ahead of print.
PMID: 35196255 Review.
5.
Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes. Odabas FO, Uca AU, Akdag T, Demirdögen F, Altas M, Tokgoz OS.
Arq Neuropsiquiatr. 2022 Feb 21:S0004-282X2022005003212. doi: 10.1590/0004-282X-ANP-2021-0202. Online ahead of print.
PMID: 35195231
6.
Disease course of Chronic Relapsing Inflammatory Optic Neuropathy (CRION) in a single care center. Molina-Carrión LE, Lira-Tecpa J, Jiménez-Arellano MP, Cruz-Domínguez MP, Medina G.
Arq Neuropsiquiatr. 2022 Feb 21:S0004-282X2022005003211. doi: 10.1590/0004-282X-ANP-2021-0157. Online ahead of print.
PMID: 35195230
7.
Effect of 12 weeks of aquatic strength training on individuals with multiple sclerosis. Scorcine C, Veríssimo S, Couto A, Madureira F, Guedes D, Fragoso YD, Colantonio E.
Arq Neuropsiquiatr. 2022 Feb 21:S0004-282X2022005003205. doi: 10.1590/0004-282X-ANP-2020-0541. Online ahead of print.
PMID: 35195224
8.
Serum levels of irisin and nesfatin-1 in multiple sclerosis. Altaş M, Uca AU, Akdağ T, Odabaş FÖ, Tokgöz OS.
Arq Neuropsiquiatr. 2022 Feb 21:S0004-282X2022005003204. doi: 10.1590/0004-282X-ANP-2020-0520. Online ahead of print.
PMID: 35195223
9.
Coexistence of restless legs syndrome and multiple sclerosis aggravates anxiety and depression. Sevim S, Demirkiran M, Terzi M, Yüceyar N, Taşdelen B, Idiman E, Kürtüncü M, Boz C, Tuncel D, Karabudak R, Siva A, Özcan A, Neyal M, Göksel BK, Gazaloğlu GB, Balal M, Şen S, Baklan MA, Gündüz T, Tuncer A, Uygunoğlu U.
Arq Neuropsiquiatr. 2022 Feb 21:S0004-282X2022005003202. doi: 10.1590/0004-282X-ANP-2020-0400. Online ahead of print.
PMID: 35195221
10.
“Stable” vs. “silent progressive multiple sclerosis”: a real-world retrospective clinical imaging Brazilian study. Figueira GMA, Soares PV, Silveira RCD, Figueira FFA.
Arq Neuropsiquiatr. 2022 Feb 21:S0004-282X2022005003201. doi: 10.1590/0004-282X-ANP-2020-0234. Online ahead of print.
PMID: 35195220
11.
Curing inflammatory diseases using phosphorous dendrimers. Caminade AM, Turrin CO, Poupot R.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 Feb 22:e1783. doi: 10.1002/wnan.1783. Online ahead of print.
PMID: 35194953 Review.
12.
[Post-corona fatigue-a familiar picture in a new guise?]. Buchberger B, Zwierlein R, Rohde V.
Onkologe (Berl). 2022 Feb 17:1-6. doi: 10.1007/s00761-022-01102-1. Online ahead of print.
PMID: 35194336 Free PMC article. German.
13.
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. Räuber S, Korsen M, Huntemann N, Rolfes L, Müntefering T, Dobelmann V, Hermann AM, Kölsche T, von Wnuck Lipinski K, Schroeter CB, Nelke C, Regner-Nelke L, Ingwersen J, Pawlitzki M, Teegen B, Barnett MH, Hartung HP, Aktas O, Albrecht P, Levkau B, Melzer N, Ruck T, Meuth SG, Kremer D.
J Neurol Neurosurg Psychiatry. 2022 Feb 22:jnnp-2021-328197. doi: 10.1136/jnnp-2021-328197. Online ahead of print.
PMID: 35193952
14.
Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study. Etemadifar M, Abhari AP, Nouri H, Salari M, Maleki S, Amin A, Sedaghat N.
BMC Neurol. 2022 Feb 22;22(1):64. doi: 10.1186/s12883-022-02590-9.
PMID: 35193507
15.
Role of microbiome and metabolome in the pathobiology of MS. Mangalam AK, Giri S.
Clin Immunol. 2022 Feb;235:108934. doi: 10.1016/j.clim.2022.108934. Epub 2022 Jan 20.
PMID: 35066173 No abstract available.
16.
Clinical heterogeneity in patients with myoclonus associated to COVID-19. Álvarez Bravo G, Sánchez Cirera L, Angerri Nadal M, Ramió I Torrentà L.
Neurol Sci. 2022 Mar;43(3):1587-1592. doi: 10.1007/s10072-021-05802-1. Epub 2022 Jan 6.
PMID: 34988717 Free PMC article.
1.
Application of extracellular vesicles derived from mesenchymal stem cells as potential therapeutic tools in autoimmune and rheumatic diseases. Huldani H, Abdalkareem Jasim S, Olegovich Bokov D, Kamal Abdelbasset W, Nader Shalaby M, Thangavelu L, Margiana R, Qasim MT.
Int Immunopharmacol. 2022 Feb 19;106:108634. doi: 10.1016/j.intimp.2022.108634. Online ahead of print.
PMID: 35193053 Review.
2.
Correction: Blood-brain barrier breakdown in non-enhancing multiple sclerosis lesions detected by 7-Tesla MP2RAGE ΔT1 mapping. Choi S, Spini M, Hua J, Harrison DM.
PLoS One. 2022 Feb 22;17(2):e0264452. doi: 10.1371/journal.pone.0264452. eCollection 2022.
PMID: 35192677
3.
Ocrelizumab: A Review in Multiple Sclerosis. Lamb YN.
Drugs. 2022 Feb 22:1-12. doi: 10.1007/s40265-022-01672-9. Online ahead of print.
PMID: 35192158 Free PMC article. Review.
4.
Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. Cobo-Calvo A, Zabalza A, Río J, Arrambide G, Otero-Romero S, Tagliani P, Cárdenas-Robledo S, Castillo M, Espejo C, Rodriguez M, Carbonell P, Rodríguez B, Midaglia L, Vidal-Jordana Á, Tur C, Galan I, Castillo J, Comabella M, Nos C, Auger C, Tintoré M, Rovira À, Montalban X, Sastre-Garriga J.
J Neurol. 2022 Feb 22:1. doi: 10.1007/s00415-022-11019-9. Online ahead of print.
PMID: 35192034 Free PMC article. No abstract available.
5.
The role of glial cells in multiple sclerosis disease progression. Healy LM, Stratton JA, Kuhlmann T, Antel J.
Nat Rev Neurol. 2022 Feb 21. doi: 10.1038/s41582-022-00624-x. Online ahead of print.
PMID: 35190704 Review.
6.
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial. Vermersch P, Brieva-Ruiz L, Fox RJ, Paul F, Ramio-Torrenta L, Schwab M, Moussy A, Mansfield C, Hermine O, Maciejowski M; AB07002 Study Group.
Neurol Neuroimmunol Neuroinflamm. 2022 Feb 21;9(3):e1148. doi: 10.1212/NXI.0000000000001148. Print 2022 May.
PMID: 35190477
7.
Flu vaccination in multiple sclerosis patients: a monocentric prospective vaccine-vigilance study. Maniscalco GT, Scavone C, Moreggia O, Di Giulio Cesare D, Aiezza ML, Guglielmi G, Longo G, Maiolo M, Raiola E, Russo G, Capuano A.
Expert Opin Drug Saf. 2022 Feb 22. doi: 10.1080/14740338.2022.2044787. Online ahead of print.
PMID: 35189777
1.
Managing neuropsychological impairment in multiple sclerosis – Controlled study on a standardized metacognitive intervention (MaTiMS). Pöttgen J, Friede T, Lau S, Gold SM, Letsch C, Bender G, Flachenecker P, Heesen C, Penner IK.
Mult Scler Relat Disord. 2022 Feb 13;59:103687. doi: 10.1016/j.msard.2022.103687. Online ahead of print.
PMID: 35189580
2.
Self-perceived versus physician documented adverse events in patients with multiple sclerosis REGIMS-a pharmacovigilance registry for patients with multiple sclerosis in Germany. Moeller SN, Simbrich A, Berger K; REGIMS Investigators.
Mult Scler Relat Disord. 2022 Feb 12;59:103684. doi: 10.1016/j.msard.2022.103684. Online ahead of print.
PMID: 35189579
3.
Therapeutic opportunities for targeting cellular senescence in progressive multiple sclerosis. Sutter PA, McKenna MG, Imitola J, Pijewski RS, Crocker SJ.
Curr Opin Pharmacol. 2022 Feb 18;63:102184. doi: 10.1016/j.coph.2022.102184. Online ahead of print.
PMID: 35189476 Review.
4.
Deformation-based morphometry identifies deep brain structures protected by ocrelizumab. Song Z, Krishnan A, Gaetano L, Tustison NJ, Clayton D, de Crespigny A, Bengtsson T, Jia X, Carano RAD.
Neuroimage Clin. 2022 Feb 14;34:102959. doi: 10.1016/j.nicl.2022.102959. Online ahead of print.
PMID: 35189455
5.
Regulation of activated microglia and macrophages by systemically administered DNA/RNA heteroduplex oligonucleotides. Nishi R, Ohyagi M, Nagata T, Mabuchi Y, Yokota T.
Mol Ther. 2022 Feb 18:S1525-0016(22)00103-4. doi: 10.1016/j.ymthe.2022.02.019. Online ahead of print.
PMID: 35189344
6.
The MULTI-ACT model: the path forward for participatory and anticipatory governance in health research and care. Zaratin P, Bertorello D, Guglielmino R, Devigili D, Brichetto G, Tageo V, Dati G, Kramer S, Battaglia MA, Di Luca M.
Health Res Policy Syst. 2022 Feb 17;20(1):22. doi: 10.1186/s12961-022-00825-2.
PMID: 35177080 Free PMC article.
1.
Coupling of brain activity and structural network in multiple sclerosis: A graph frequency analysis study. Ye C, Huang J, Liang L, Yan Z, Qi Z, Kang X, Liu Z, Dong H, Lv H, Ma T, Lu J.
J Neurosci Res. 2022 Feb 20. doi: 10.1002/jnr.25028. Online ahead of print.
PMID: 35184336
2.
The expression pattern of VISTA in the PBMCs of relapsing-remitting multiple sclerosis patients: A single-cell RNA sequencing-based study. Derakhshani A, Asadzadeh Z, Baradaran B, Safarpour H, Rahmani S, Leone P, Abdoli Shadbad M, Hosseinkhani N, Ghasemigol M, Ayromlou H, Ahmadi H, Pouya S, Shojaee M, Tabrizi NJ, Miraki Feriz A, Safarzadeh E, Racanelli V.
Biomed Pharmacother. 2022 Feb 17;148:112725. doi: 10.1016/j.biopha.2022.112725. Online ahead of print.
PMID: 35183994
3.
Discovery of a novel and potent inhibitor with differential species-specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis. Jiao Y, Nan J, Mu B, Zhang Y, Zhou N, Yang S, Zhang S, Lin W, Wang F, Xia A, Cao Z, Chen P, Pan Z, Lin G, Pan S, Bin H, Li L, Yang S.
Eur J Med Chem. 2022 Feb 11;232:114194. doi: 10.1016/j.ejmech.2022.114194. Online ahead of print.
PMID: 35183871
4.
Epidemiology of multiple sclerosis in West bank of Palestine. Abuawad M, Ziyadeh-Isleem A, Alkaiyat A, Ziyadeh J, Afifi B, Saidi M, Sous A.
Mult Scler Relat Disord. 2022 Feb 13;59:103686. doi: 10.1016/j.msard.2022.103686. Online ahead of print.
PMID: 35183818
5.
Cognitive function in pediatric-onset relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Fabri TL, O’Mahony J, Fadda G, Gur RE, Gur RC, Yeh EA, Banwell BL, Till C.
Mult Scler Relat Disord. 2022 Feb 14;59:103689. doi: 10.1016/j.msard.2022.103689. Online ahead of print.
PMID: 35183817
6.
Developing tools to evaluate quality of care management for patients living with multiple sclerosis: An original French initiative. Veillard D, Deburghgraeve V, Le Page E, Debouverie M, Wiertlewski S, Gallien P, Edan G.
Rev Neurol (Paris). 2022 Feb 16:S0035-3787(22)00163-1. doi: 10.1016/j.neurol.2021.12.011. Online ahead of print.
PMID: 35183366
1.
Multiple Sclerosis Performance Test (MSPT): Normative study of 428 healthy participants ages 18 to 89. Rao SM, Sokolowski M, Strober LB, Miller JB, Norman MA, Levitt N, Williams JR, de Moor C.
Mult Scler Relat Disord. 2022 Jan 30;59:103644. doi: 10.1016/j.msard.2022.103644. Online ahead of print.
PMID: 35182881
2.
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis. Ciampi E, Uribe-San-Martin R, Soler B, García L, Guzman J, Pelayo C, Jürgensen L, Guzman I, Vera F, Galleguillos L, Cárcamo C.
Mult Scler Relat Disord. 2022 Feb 13;59:103690. doi: 10.1016/j.msard.2022.103690. Online ahead of print.
PMID: 35182880
3.
The degree of cortical plasticity correlates with cognitive performance in patients with Multiple Sclerosis. Balloff C, Penner IK, Ma M, Georgiades I, Scala L, Troullinakis N, Graf J, Kremer D, Aktas O, Hartung HP, Meuth SG, Schnitzler A, Groiss SJ, Albrecht P.
Brain Stimul. 2022 Feb 16:S1935-861X(22)00035-3. doi: 10.1016/j.brs.2022.02.007. Online ahead of print.
PMID: 35182811
4.
TINY IN SIZE, BIG IN IMPACT: EXTRACELLULAR VESICLES AS MODULATORS OF MOOD, ANXIETY AND NEURODEVELOPMENTAL DISORDERS. Duarte-Silva E, Oriá AC, Mendonça IP, de Melo MG, Paiva IHR, Maes M, Joca SRL, Peixoto CA.
Neurosci Biobehav Rev. 2022 Feb 16:104582. doi: 10.1016/j.neubiorev.2022.104582. Online ahead of print.
PMID: 35182538 Review.
5.
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli Ö, Maceski A, Oechtering J, Achtnichts L, Conen D, Derfuss T, Lalive PH, Mueller C, Müller S, Naegelin Y, Oksenberg JR, Pot C, Salmen A, Willemse E, Kockum I, Blennow K, Zetterberg H, Gobbi C, Kappos L, Wiendl H, Berger K, Sormani MP, Granziera C, Piehl F, Leppert D, Kuhle J; NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group.
Lancet Neurol. 2022 Mar;21(3):246-257. doi: 10.1016/S1474-4422(22)00009-6.
PMID: 35182510
6.
The reality of multiple sclerosis assessment in middle-income countries – Authors’ reply. Rovira À, Traboulsee A, Reich DS, Wattjes MP; MAGNIMS Study Group, CMSC, and NAIMS.
Lancet Neurol. 2022 Mar;21(3):215-216. doi: 10.1016/S1474-4422(22)00041-2.
PMID: 35182502 No abstract available.
7.
The reality of multiple sclerosis assessment in middle-income countries. Abramov DM, de Silva DS, Salles TRS, Galhanone PR, Lazarev VV.
Lancet Neurol. 2022 Mar;21(3):215. doi: 10.1016/S1474-4422(22)00042-4.
PMID: 35182501 No abstract available.
8.
Multiple sclerosis: two decades of progress. Cree BAC, Oksenberg JR, Hauser SL.
Lancet Neurol. 2022 Mar;21(3):211-214. doi: 10.1016/S1474-4422(22)00040-0.
PMID: 35182500 No abstract available.
9.
The prognostic value of neurofilament light chain in serum. Sellebjerg F, Magyari M.
Lancet Neurol. 2022 Mar;21(3):207-208. doi: 10.1016/S1474-4422(22)00034-5.
PMID: 35182499 No abstract available.
10.
Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases. Stathopoulos P, Dalakas MC.
Neurotherapeutics. 2022 Feb 18. doi: 10.1007/s13311-022-01196-w. Online ahead of print.
PMID: 35182380 Review.
11.
Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis. Khan H, Ghori FK, Ghani U, Javed A, Zahid S.
Mol Biol Rep. 2022 Feb 18. doi: 10.1007/s11033-022-07223-5. Online ahead of print.
PMID: 35182322 Review.
12.
Incidence of bladder cancer in neuro-urological patients in France: a nationwide study. Michel F, Cancrini F, Bensadoun H, Cussenot O, Guillot-Tantay C, Rouprêt M, Karsenty G, Phé V.
World J Urol. 2022 Feb 19. doi: 10.1007/s00345-022-03955-y. Online ahead of print.
PMID: 35182207
13.
Cellular specificity of mitochondrial and immunometabolic features in major depression. Brasanac J, Gamradt S, Otte C, Milaneschi Y, Monzel AS, Picard M, Gold SM.
Mol Psychiatry. 2022 Feb 18. doi: 10.1038/s41380-022-01473-2. Online ahead of print.
PMID: 35181755 No abstract available.
14.
Targeting IFN-λ Signaling Promotes Recovery from Central Nervous System Autoimmunity. Manivasagam S, Williams JL, Vollmer LL, Bollman B, Bartleson JM, Ai S, Wu GF, Klein RS.
J Immunol. 2022 Feb 18:ji2101041. doi: 10.4049/jimmunol.2101041. Online ahead of print.
PMID: 35181638
15.
Factors supporting availability of home-based Neuromodulation using remote supervision in middle-income countries; Brazil experience. Silva-Filho E, Pilloni G, Charvet LE, Fregni F, Brunoni AR, Bikson M.
Brain Stimul. 2022 Feb 15:S1935-861X(22)00033-X. doi: 10.1016/j.brs.2022.02.005. Online ahead of print.
PMID: 35181531 No abstract available.
16.
Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients. Lefort M, Le Corre G, Le Page E, Rizzato C, Le Port D, Michel L, Kerbrat A, Leray E, Edan G.
Rev Neurol (Paris). 2022 Feb 15:S0035-3787(22)00043-1. doi: 10.1016/j.neurol.2021.11.014. Online ahead of print.
PMID: 35181157
17.
Choroid plexus-selective inactivation of adenosine A2A receptors protects against T cell infiltration and experimental autoimmune encephalomyelitis. Zheng W, Feng Y, Zeng Z, Ye M, Wang M, Liu X, Tang P, Shang H, Sun X, Lin X, Wang M, Li Z, Weng Y, Guo W, Vakal S, Chen JF.
J Neuroinflammation. 2022 Feb 18;19(1):52. doi: 10.1186/s12974-022-02415-z.
PMID: 35180864
1.
Retinal nerve fiber and ganglion cell complex layer thicknesses mirror brain atrophy in patients with relapsing-remitting multiple sclerosis. Glasner P, Sabisz A, Chylińska M, Komendziński J, Wyszomirski A, Karaszewski B.
Restor Neurol Neurosci. 2022 Feb 17. doi: 10.3233/RNN-211176. Online ahead of print.
PMID: 35180139
2.
Effectiveness of non-pharmacological rehabilitation interventions in pain management in patients with multiple sclerosis: Systematic review and meta-analysis. Hadoush H, Alawneh A, Kassab M, Al-Wardat M, Al-Jarrah M.
NeuroRehabilitation. 2022 Feb 15. doi: 10.3233/NRE-210328. Online ahead of print.
PMID: 35180138 Review.
3.
Hypnotherapy as a Nonpharmacological Treatment for the Psychological Symptoms of Multiple Sclerosis. Maresca G, Nocito V, Lo Buono V, Latella D, Di Cara M, Formica C, Carnazza L, Sessa E, Bramanti P, Corallo F.
Altern Ther Health Med. 2022 Feb 18:AT7070. Online ahead of print.
PMID: 35180100
4.
Gut-oriented interventions in patients with multiple sclerosis: fact or fiction? Martinelli V, Albanese M, Altieri M, Annovazzi P, Arabi S, Bucello S, Caleri F, Cerqua R, Costanzi C, Cottone S, Dalla Costa G, Direnzo V, Fantozzi R, Favaretto A, Lorefice L, Montini F, Noce A, Plewnia K, Repice AM, Sacco R, Vecchio D.
Eur Rev Med Pharmacol Sci. 2022 Feb;26(3):935-946. doi: 10.26355/eurrev_202202_28003.
PMID: 35179760
5.
The MULTI-ACT model: the path forward for participatory and anticipatory governance in health research and care. Zaratin P, Bertorello D, Guglielmino R, Devigili D, Brichetto G, Tageo V, Dati G, Kramer S, Battaglia MA, Di Luca M.
Health Res Policy Syst. 2022 Feb 17;20(1):22. doi: 10.1186/s12961-022-00825-2.
PMID: 35177080
1.
Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis. Askari M, Mirmosayyeb O, Ghaffary EM, Ghoshouni H, Shaygannejad V, Ghajarzadeh M.
Mult Scler Relat Disord. 2022 Feb 9;59:103680. doi: 10.1016/j.msard.2022.103680. Online ahead of print.
PMID: 35176641 Review.
2.
Uncovering patterns of real-world psychological support seeking and the patient experience in multiple sclerosis. Morris-Bankole H, Ho AK.
Mult Scler Relat Disord. 2022 Feb 4;59:103666. doi: 10.1016/j.msard.2022.103666. Online ahead of print.
PMID: 35176640
3.
Recent advancements in nanoparticle-mediated approaches for restoration of multiple sclerosis. Rahiman N, Mohammadi M, Alavizadeh SH, Arabi L, Badiee A, Jaafari MR.
J Control Release. 2022 Feb 14:S0168-3659(22)00083-9. doi: 10.1016/j.jconrel.2022.02.009. Online ahead of print.
PMID: 35176392 Review.
4.
Caudovirales bacteriophages are associated with improved executive function and memory in flies, mice, and humans. Mayneris-Perxachs J, Castells-Nobau A, Arnoriaga-Rodríguez M, Garre-Olmo J, Puig J, Ramos R, Martínez-Hernández F, Burokas A, Coll C, Moreno-Navarrete JM, Zapata-Tona C, Pedraza S, Pérez-Brocal V, Ramió-Torrentà L, Ricart W, Moya A, Martínez-García M, Maldonado R, Fernández-Real JM.
Cell Host Microbe. 2022 Feb 11:S1931-3128(22)00049-X. doi: 10.1016/j.chom.2022.01.013. Online ahead of print.
PMID: 35176247
5.
The Relationship Between Adaptation to Disease and Self-care Agency Levels in Patients With Multiple Sclerosis. Yurttaş A, Bayram A.
J Neurosci Nurs. 2022 Feb 16. doi: 10.1097/JNN.0000000000000630. Online ahead of print.
PMID: 35175988
6.
[Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial]. Boyko AN, Boyko OV, Bakhtiyarova KZ, Gusev EI, Dudin VA, Zaslavsky LG, Malkova NA, Parshina YV, Poverennova IY, Siverceva SA, Totolyan NA, Shchur SG, Fedulov AS, Khabirov FA, Bolsun DD, Zinkina-Orikhan AV, Linkova YN, Chernovskaya TV.
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(1):62-71. doi: 10.17116/jnevro202212201162.
PMID: 35175704 Russian.
7.
Effect of home-based virtual reality training and telerehabilitation on balance in individuals with Parkinson disease, multiple sclerosis, and stroke: a systematic review and meta-analysis. Truijen S, Abdullahi A, Bijsterbosch D, van Zoest E, Conijn M, Wang Y, Struyf N, Saeys W.
Neurol Sci. 2022 Feb 17. doi: 10.1007/s10072-021-05855-2. Online ahead of print.
PMID: 35175439 Review.
8.
Mental Practice and Manipulative Skills Training Among People With Multiple Sclerosis: A Pilot Study. Sánchez-Herrera-Baeza P, García-Bravo C, Huertas-Hoyas E, Florencio LL, Martínez-Piédrola RM, Pérez-Corrales J, Sánchez-Camarero C, Pérez-de-Heredia-Torres M.
Am J Occup Ther. 2022 Mar 1;76(2):7602205040. doi: 10.5014/ajot.2022.044479.
PMID: 35175336
9.
Intensive circuit class therapy in patients with relapsing-remitting multiple sclerosis. Kocica J, Kolcava J, Sladeckova M, Stourac P, Vlckova E, Dosbaba F, Kratochvilova J, Bednarik J.
J Rehabil Med. 2022 Feb 17. doi: 10.2340/jrm.v54.2027. Online ahead of print.
PMID: 35174869
10.
Improving Awareness Could Transform Outcomes in Degenerative Cervical Myelopathy [AO Spine RECODE-DCM Research Priority Number 1]. Davies BM, Mowforth O, Wood H, Karimi Z, Sadler I, Tetreault L, Milligan J, Wilson JRF, Kalsi-Ryan S, Furlan JC, Kawaguchi Y, Ito M, Zipser CM, Boerger TF, Vaccaro AR, Murphy RKJ, Hutton M, Rodrigues-Pinto R, Koljonen PA, Harrop JS, Aarabi B, Rahimi-Movaghar V, Kurpad SN, Guest JD, Wilson JR, Kwon BK, Kotter MRN, Fehlings MG.
Global Spine J. 2022 Feb;12(1_suppl):28S-38S. doi: 10.1177/21925682211050927.
PMID: 35174734
11.
Stem cell therapy for COVID-19 pneumonia. Kebria MM, Milan PB, Peyravian N, Kiani J, Khatibi S, Mozafari M.
Mol Biomed. 2022 Feb 17;3(1):6. doi: 10.1186/s43556-021-00067-8.
PMID: 35174448 Review.
12.
The forgotten tract of vision in multiple sclerosis: vertical occipital fasciculus, its fiber properties, and visuospatial memory. Abdolalizadeh A, Mohammadi S, Aarabi MH.
Brain Struct Funct. 2022 Feb 17. doi: 10.1007/s00429-022-02464-3. Online ahead of print.
PMID: 35174417
13.
Potentials and barriers of using digital tools for collecting daily measurements in multiple sclerosis research. Katrine W, Ritzel SB, Caroline K, Marie L, Olsgaard BS, Lasse S.
Digit Health. 2021 Nov 26;7:20552076211055552. doi: 10.1177/20552076211055552. eCollection 2021 Jan-Dec.
PMID: 35173979 Free PMC article.
14.
Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. Allen-Philbey K, De Trane S, Mao Z, Álvarez-González C, Mathews J, MacDougall A, Stennett A, Zhou X, Yildiz O, Adams A, Bianchi L, Blain C, Chapman C, Chung K, Constantinescu CS, Dalton C, Farrell RA, Fisniku L, Ford H, Gran B, Hobart J, Khaleeli Z, Mattoscio M, Pavitt S, Pearson O, Peruzzotti-Jametti L, Scalfari A, Sharrack B, Silber E, Tallantyre EC, Webb S, Turner BP, Marta M, Gnanapavan S, Juliusson G, Giovannoni G, Baker D, Schmierer K.
Ther Adv Neurol Disord. 2021 Nov 25;14:17562864211057661. doi: 10.1177/17562864211057661. eCollection 2021.
PMID: 35173808 Free PMC article.
15.
Brain Antigens Stimulate Proliferation of T Lymphocytes With a Pathogenic Phenotype in Multiple Sclerosis Patients. Gottlieb A, Pham HPT, Lindsey JW.
Front Immunol. 2022 Jan 31;13:835763. doi: 10.3389/fimmu.2022.835763. eCollection 2022.
PMID: 35173742 Free PMC article.
16.
Gut Microbiota Composition Is Related to AD Pathology. Verhaar BJH, Hendriksen HMA, de Leeuw FA, Doorduijn AS, van Leeuwenstijn M, Teunissen CE, Barkhof F, Scheltens P, Kraaij R, van Duijn CM, Nieuwdorp M, Muller M, van der Flier WM.
Front Immunol. 2022 Jan 31;12:794519. doi: 10.3389/fimmu.2021.794519. eCollection 2021.
PMID: 35173707 Free PMC article.
17.
Women’s Health in Multiple Sclerosis: A Scoping Review. Ross L, Ng HS, O’Mahony J, Amato MP, Cohen JA, Harnegie MP, Hellwig K, Tintore M, Vukusic S, Marrie RA.
Front Neurol. 2022 Jan 31;12:812147. doi: 10.3389/fneur.2021.812147. eCollection 2021.
PMID: 35173669 Free PMC article.
18.
The Multiple Sclerosis Prodrome: Evidence to Action. Tremlett H, Munger KL, Makhani N.
Front Neurol. 2022 Jan 31;12:761408. doi: 10.3389/fneur.2021.761408. eCollection 2021.
PMID: 35173664 Free PMC article.
19.
Twin study reveals non-heritable immune perturbations in multiple sclerosis. Ingelfinger F, Gerdes LA, Kavaka V, Krishnarajah S, Friebel E, Galli E, Zwicky P, Furrer R, Peukert C, Dutertre CA, Eglseer KM, Ginhoux F, Flierl-Hecht A, Kümpfel T, De Feo D, Schreiner B, Mundt S, Kerschensteiner M, Hohlfeld R, Beltrán E, Becher B.
Nature. 2022 Feb 16. doi: 10.1038/s41586-022-04419-4. Online ahead of print.
PMID: 35173329
20.
Function and therapeutic value of astrocytes in neurological diseases. Lee HG, Wheeler MA, Quintana FJ.
Nat Rev Drug Discov. 2022 Feb 16. doi: 10.1038/s41573-022-00390-x. Online ahead of print.
PMID: 35173313 Review.
21.
Artificial double inversion recovery images can substitute conventionally acquired images: an MRI-histology study. Bouman PM, Steenwijk MD, Geurts JJG, Jonkman LE.
Sci Rep. 2022 Feb 16;12(1):2620. doi: 10.1038/s41598-022-06546-4.
PMID: 35173226
22.
Advanced Diffusion MR Imaging for Multiple Sclerosis in the Brain and Spinal Cord. Hori M, Maekawa T, Kamiya K, Hagiwara A, Goto M, Takemura MY, Fujita S, Andica C, Kamagata K, Cohen-Adad J, Aoki S.
Magn Reson Med Sci. 2022 Feb 15. doi: 10.2463/mrms.rev.2021-0091. Online ahead of print.
PMID: 35173096
23.
Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review. Lie IA, Weeda MM, Mattiesing RM, Mol MAE, Pouwels PJW, Barkhof F, Torkildsen Ø, Bø L, Myhr KM, Vrenken H.
Neurology. 2022 Feb 16:10.1212/WNL.0000000000200006. doi: 10.1212/WNL.0000000000200006. Online ahead of print.
PMID: 35173016
1.
Serum molecular biomarkers in neuromyelitis optica and multiple sclerosis. Fu CC, Gao C, Zhang HH, Mao YQ, Lu JQ, Petritis B, Huang AS, Yang XG, Long YM, Huang RP.
Mult Scler Relat Disord. 2022 Jan 20;59:103527. doi: 10.1016/j.msard.2022.103527. Online ahead of print.
PMID: 35172264 No abstract available.
2.
Trait mindfulness, emotion dysregulation, and depression in individuals with multiple sclerosis. Duraney EJ, Schirda B, Nicholas JA, Prakash RS.
Mult Scler Relat Disord. 2022 Feb 2;59:103651. doi: 10.1016/j.msard.2022.103651. Online ahead of print.
PMID: 35172263
3.
Initial experience with magnetic resonance-guided focused ultrasound stereotactic surgery for central brain lesions in young adults. Tierney TS, Alavian KN, Altman N, Bhatia S, Duchowny M, Hyslop A, Jayakar P, Resnick T, Wang S, Miller I, Ragheb J.
J Neurosurg. 2022 Jan 14:1-8. doi: 10.3171/2021.10.JNS21416. Online ahead of print.
PMID: 35171812
4.
Multiple Sclerosis Lesion Analysis in Brain Magnetic Resonance Images: Techniques and Clinical Applications. Ma Y, Zhang C, Cabezas M, Song Y, Tang Z, Liu D, Cai W, Barnett M, Wang C.
IEEE J Biomed Health Inform. 2022 Feb 16;PP. doi: 10.1109/JBHI.2022.3151741. Online ahead of print.
PMID: 35171783
5.
Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab. Altieri M, Capuano R, Conte M, Donnarumma G, Grimaldi E, Coppola N, Galdiero M, d’Ambrosio A, Tedeschi G, Gallo A.
Neurol Sci. 2022 Feb 16. doi: 10.1007/s10072-022-05940-0. Online ahead of print.
PMID: 35171373
6.
Associations Between Neuropsychiatric Symptoms and Neuropathological Diagnoses of Alzheimer Disease and Related Dementias. Devanand DP, Lee S, Huey ED, Goldberg TE.
JAMA Psychiatry. 2022 Feb 16. doi: 10.1001/jamapsychiatry.2021.4363. Online ahead of print.
PMID: 35171235
7.
Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: an update. Messias K, Marques VD, Messias A.
Arq Bras Oftalmol. 2022 Feb 14:S0004-27492022005003210. doi: 10.5935/0004-2749.20230012. Online ahead of print.
PMID: 35170658
8.
Glycogen Synthase Kinase 3β Involvement in Neuroinflammation and Neurodegenerative Diseases. Gianferrara T, Cescon E, Grieco I, Spalluto G, Federico S.
Curr Med Chem. 2022 Feb 16. doi: 10.2174/0929867329666220216113517. Online ahead of print.
PMID: 35170406
9.
Pathological observations of a long spinal cord lesion in a patient with multiple sclerosis. Yabata H, Saito Y, Fukuoka T, Akagi A, Riku Y, Sone J, Miyahara H, Doyu M, Yoshida M, Iwasaki Y.
Neuropathology. 2022 Feb 15. doi: 10.1111/neup.12800. Online ahead of print.
PMID: 35170108
10.
Immunological predictors of dimethyl fumarate-induced lymphopenia. Diebold M, Galli E, Kopf A, Sanderson N, Callegari I, Ingelfinger F, Núñez NG, Benkert P, Kappos L, Kuhle J, Becher B, Claassen M, Derfuss T.
Ann Neurol. 2022 Feb 16. doi: 10.1002/ana.26328. Online ahead of print.
PMID: 35170072
11.
Exploiting flow cytometry for the unbiased quantification of protein inclusions in Caenorhabditis elegans. Claesson K, Chew YL, Ecroyd H.
J Neurochem. 2022 Feb 15. doi: 10.1111/jnc.15591. Online ahead of print.
PMID: 35170035
12.
Epstein-Barr virus sparks brain autoimmunity in multiple sclerosis. Wekerle H.
Nature. 2022 Feb 15. doi: 10.1038/d41586-022-00382-2. Online ahead of print.
PMID: 35169323 No abstract available.
13.
A deep learning-based toolbox for Automated Limb Motion Analysis (ALMA) in murine models of neurological disorders. Aljovic A, Zhao S, Chahin M, de la Rosa C, Van Steenbergen V, Kerschensteiner M, Bareyre FM.
Commun Biol. 2022 Feb 15;5(1):131. doi: 10.1038/s42003-022-03077-6.
PMID: 35169263
14.
[Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex(TSC-SEGA)]. Ichikawa T, Niida Y.
No Shinkei Geka. 2022 Jan;50(1):111-121. doi: 10.11477/mf.1436204536.
PMID: 35169091 Japanese.
15.
Population-Based Study of Nonelective Postpartum Readmissions in Women With Stroke, Migraine, Multiple Sclerosis, and Myasthenia Gravis. McElwee Decker B, Thibault D, Davis KA, Willis AW.
Neurology. 2022 Feb 15:10.1212/WNL.Online ahead of print.
PMID: 35169012
16.
Protocols for measuring the stability and cytotoxicity of cyclotides. Huang YH, Kan MW, Craik DJ.
Methods Enzymol. 2022;663:19-40. doi: 10.1016/bs.mie.2021.09.007. Epub 2021 Nov 9.
PMID: 35168789
17.
Human herpesvirus 6 infection as a trigger of multiple sclerosis: an update of recent literature. Voumvourakis KI, Fragkou PC, Kitsos DK, Foska K, Chondrogianni M, Tsiodras S.
BMC Neurol. 2022 Feb 15;22(1):57. doi: 10.1186/s12883-022-02568-7.
PMID: 35168545
18.
Obesity and adipose tissue-derived cytokines in the pathogenesis of Multiple Sclerosis. Daryabor G, Amirghofran Z, Gholijani N, Bemani P.
Endocr Metab Immune Disord Drug Targets. 2022 Feb 15. doi: 10.2174/1871530322666220215110041. Online ahead of print.
PMID: 35168514
19.
A systematic review of self-concept change in multiple sclerosis. Emery H, Padgett C, Ownsworth T, Honan CA.
Neuropsychol Rehabil. 2022 Feb 16:1-40. doi: 10.1080/09602011.2022.2030367. Online ahead of print.
PMID: 35168496
20.
Predictors of Glucocorticoid Use for Acute Optic Neuritis in the United States, 2005-2019. De Lott LB, Lin CC, Burke JF, Wallace B, Saukkonen D, Waljee AK, Kerber KA.
Ophthalmic Epidemiol. 2022 Feb 16:1-7. doi: 10.1080/09286586.2022.2034167. Online ahead of print.
PMID: 35168450
21.
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Marignier R, Pittock SJ, Paul F, Kim HJ, Bennett JL, Weinshenker BG, Wingerchuk DM, Green AJ, Cree BAC; N-MOmentum study investigators.
Mult Scler Relat Disord. 2022 Jan;57:103356. doi: 10.1016/j.msard.2021.103356. Epub 2021 Nov 1.
PMID: 35158465 Clinical Trial.
22.
The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2. Krasemann S, Haferkamp U, Pfefferle S, Woo MS, Heinrich F, Schweizer M, Appelt-Menzel A, Cubukova A, Barenberg J, Leu J, M, Pless O.
Stem Cell Reports. 2022 Feb 8;17(2):307-320. doi: 10.1016/j.stemcr.2021.12.011. Epub 2022 Jan 20.
PMID: 35063125 Free PMC article.
23.
A much needed metric: Defining reliable and statistically meaningful change of the oral version Symbol Digit Modalities Test (SDMT). Strober LB, Bruce JM, Arnett PA, Alschuler KN, DeLuca J, Chiaravalloti N, Lebkuecher A, Di Benedetto M, Cozart J, Thelen J, Cadden M, Guty E, Román CAF.
Mult Scler Relat Disord. 2022 Jan;57:103405. doi: 10.1016/j.msard.2021.103405. Epub 2021 Nov 16.
PMID: 34923428
24.
Characterisation of TRIM46 autoantibody-associated paraneoplastic neurological syndrome. Valencia-Sanchez C, Knight AM, Hammami MB, Guo Y, Mills JR, Kryzer TJ, Piquet AL, Amin A, Heinzelmann M, Lucchinetti CF, Lennon VA, McKeon A, Pittock SJ, Dubey D.
J Neurol Neurosurg Psychiatry. 2022 Feb;93(2):196-200. doi: 10.1136/jnnp-2021-326656. Epub 2021 Dec 17.
PMID: 34921120
25.
Clinical perspective on clinical outcome assessments in neurosarcoidosis. Moss BP, Miller DM, Culver DA.
Mult Scler Relat Disord. 2022 Jan;57:103403. doi: 10.1016/j.msard.2021.103403. Epub 2021 Nov 15.
PMID: 34875486
26.
Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. Lu A, Zimmermann HG, Specovius S, Motamedi S, Chien C, Bereuter C, Lana-Peixoto MA, Fontenelle MA, AU, Oertel FC; GJCF International Clinical Consortium for NMOSD.
J Neurol Neurosurg Psychiatry. 2022 Feb;93(2):188-195. doi: 10.1136/jnnp-2021-327412. Epub 2021 Oct 28.
PMID: 34711650 Free PMC article.
Napsat komentář
Pro přidávání komentářů se musíte nejdříve přihlásit.